PlasmaGen raises around Rs. 225 crore in a new equity round

PlasmaGen is a biopharma company headquartered in Bengaluru. It has raised around Rs. 225 crore from the UK-based Artian investments. Also, public market investors Ashish Kacholia, Anurag Bagaria, and Dushyant Patel, are pharma industry entrepreneurs, along with various HNI investors.

The new equity round also saw active participation from various returning investors, like F-Prime Capital as well as Eight Roads Ventures.

The company, which is known to make blood plasma-derived pharmaceutical items for markets involving India and many others, is going to utilize capital for worldwide expansion, product development, and the betterment of capital requirements. 

Know about PlasmaGen 

The company was founded by Vinod Nahar in 2010. It has raised around Rs. 400 crore in various rounds. It even raised $6.9 million last year in a series B round. This funding was done in September 2022 at a valuation of around $43.6 million from the renowned Eight Roads Ventures, as per the data and market research platform known as Tracxn.

According to the founder and managing director of the company, a statement stated, ‘This latest funding will strengthen the position of the company as market leader. It is our mission to be trusted and taken as the top-notch Indian biopharmaceutical company that is dedicated to improving the health and quality of life of every patient.’

He further said, ‘We are extremely grateful to every investor for doing the partnership. We will strive to improve the accessibility of blood-plasma-derived products required for every patient in India and other nations of the world.’

PlasmaGen, as a company, is known to make life-saving drugs like albumin, rabies immunoglobulin, hepatitis B immunoglobulin, RhD immunoglobulin, etc. These drugs are under the company’s name and currently work with 5000 physicians and various hospitals all over India.

Earlier in 2023, the company set up its latest manufacturing facility. This facility is for blood plasma-derived protein therapeutics in Bengaluru. It is estimated to process around 5 lakh liters of plasma each year. Also, the facility has the additional capacity to manufacture various new products. It can help various patients across the nation.

Leave a Reply

Your email address will not be published. Required fields are marked *